Inspire HGNS denied as duplicate or overlapping therapy by Aetna?
If two medications appear duplicative on paper but serve different clinical purposes (e.g., short-acting vs long-acting), the appeal needs to spell out the clinical rationale for both.
US health-plan appeal rights
Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules
Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.
What Aetna typically requires
Aetna's specific coverage criteria for inspire hgns are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.
The Aetna angle on Inspire HGNS
## Why Aetna Denies Inspire HGNS as Duplicate Therapy
Inspire (hypoglossal nerve stimulation, or HGNS) is an implantable neurostimulation device for obstructive sleep apnea. A "duplicate therapy" denial from Aetna means the plan is asserting that you are already receiving — or have access to — a therapy that achieves the same clinical goal, making the Inspire system redundant. In practice, this most often means Aetna is pointing to CPAP (continuous positive airway pressure) as the existing therapy and arguing that Inspire duplicates its function. This is a misapplication of the duplicate-therapy concept: CPAP and HGNS are mechanistically distinct therapies targeting different patient populations, and the clinical basis for HGNS explicitly addresses patients for whom CPAP has been tried and has not succeeded.
## Why This Denial Is Appealable
Duplicate-therapy denials for Inspire are widely appealed successfully. The FDA-approved indication for Inspire is specifically designed for patients who cannot use or have not adequately responded to CPAP — the very situation that makes CPAP a prior failure, not a concurrent duplicate. If your record documents CPAP intolerance or inadequate adherence and response, Aetna's own published clinical policy criteria almost certainly require that finding as a prerequisite for coverage, making the "duplicate therapy" framing internally inconsistent with Aetna's own standards.
## Your Federal Appeal Rights
- Internal appeal (ACA §2719): File a formal written appeal. Aetna must have a clinician with relevant sleep medicine expertise review any denial involving a clinical judgment about therapeutic equivalence.
- Peer-to-peer review: Your ENT or sleep specialist should request a peer-to-peer call with Aetna's medical reviewer to address the duplicate-therapy assertion directly.
- External review: After exhausting internal appeals, request independent external review. The external reviewer applies clinical standards, not Aetna's internal policy preferences.
- ERISA §503: For employer self-funded plans, demand the complete administrative record and the specific policy language supporting the duplicate-therapy finding.
- Timeline: External review must generally be requested within four months of the final internal denial.
## Documentation to Gather
1. CPAP trial documentation: Dates of CPAP initiation, compliance download data (objective adherence records from the CPAP device), documented reasons for failure or intolerance, and any clinical notes memorializing the outcome. 2. Sleep study records: Polysomnography or home sleep test results establishing the diagnosis and severity of obstructive sleep apnea. 3. Anatomical evaluation: Documentation from the implanting surgeon or ENT specialist confirming suitability for HGNS, including any drug-induced sleep endoscopy (DISE) findings. 4. Prescriber / surgeon letter: A letter from the referring sleep physician and the implanting surgeon explaining why HGNS is not duplicative of CPAP for this patient — specifically addressing the distinct mechanism of action and the patient's prior CPAP history. 5. Aetna's clinical policy: Download Aetna's current published clinical policy bulletin for hypoglossal nerve stimulation and identify every coverage criterion.
## Criteria-Mapping Structure
In your appeal, address the duplicate-therapy assertion head-on: quote the FDA-approved indication language that restricts Inspire to patients with inadequate CPAP response or intolerance, then cite the specific chart entries — dates and data — that establish that history. Use the standard two-column mapping table for all remaining Aetna coverage criteria. The combination of a direct rebuttal of the duplicate-therapy logic and a complete criteria table is the most effective structure for this denial type.
Next steps
- Find the date on the denial letter — your appeal window starts there.
- Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
- Request the insurer's claim file in writing — they must provide it.
- Submit your appeal in writing with new clinical evidence and a physician statement.
Get the letter drafted
DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.
Start my appeal — $30 with code SEO25 →